496 related articles for article (PubMed ID: 35045989)
1. Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
Ali K; Azher T; Baqi M; Binnie A; Borgia S; Carrier FM; Cavayas YA; Chagnon N; Cheng MP; Conly J; Costiniuk C; Daley P; Daneman N; Douglas J; Downey C; Duan E; Duceppe E; Durand M; English S; Farjou G; Fera E; Fontela P; Fowler R; Fralick M; Geagea A; Grant J; Harrison LB; Havey T; Hoang H; Kelly LE; Keynan Y; Khwaja K; Klein G; Klein M; Kolan C; Kronfli N; Lamontagne F; Lau R; Fralick M; Lee TC; Lee N; Lim R; Longo S; Lostun A; MacIntyre E; Malhamé I; Mangof K; McGuinty M; Mergler S; Munan MP; Murthy S; O'Neil C; Ovakim D; Papenburg J; Parhar K; Parvathy SN; Patel C; Perez-Patrigeon S; Pinto R; Rajakumaran S; Rishu A; Roba-Oshin M; Rushton M; Saleem M; Salvadori M; Scherr K; Schwartz K; Semret M; Silverman M; Singh A; Sligl W; Smith S; Somayaji R; Tan DHS; Tobin S; Todd M; Tran TV; Tremblay A; Tsang J; Turgeon A; Vakil E; Weatherald J; Yansouni C; Zarychanski R; ;
CMAJ; 2022 Feb; 194(7):E242-E251. PubMed ID: 35045989
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: an economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial.
Lau VI; Fowler R; Pinto R; Tremblay A; Borgia S; Carrier FM; Cheng MP; Conly J; Costiniuk CT; Daley P; Duan E; Durand M; Fontela PS; Farjou G; Fralick M; Geagea A; Grant J; Keynan Y; Khwaja K; Lee N; Lee TC; Lim R; O'Neil CR; Papenburg J; Semret M; Silverman M; Sligl W; Somayaji R; Tan DHS; Tsang JLY; Weatherald J; Yansouni CP; Zarychanski R; Murthy S;
CMAJ Open; 2022; 10(3):E807-E817. PubMed ID: 36199248
[TBL] [Abstract][Full Text] [Related]
3. Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial.
Spinner CD; Gottlieb RL; Criner GJ; Arribas López JR; Cattelan AM; Soriano Viladomiu A; Ogbuagu O; Malhotra P; Mullane KM; Castagna A; Chai LYA; Roestenberg M; Tsang OTY; Bernasconi E; Le Turnier P; Chang SC; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wang H; Gaggar A; Brainard DM; McPhail MJ; Bhagani S; Ahn MY; Sanyal AJ; Huhn G; Marty FM;
JAMA; 2020 Sep; 324(11):1048-1057. PubMed ID: 32821939
[TBL] [Abstract][Full Text] [Related]
4. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F; Bouscambert-Duchamp M; Hites M; Peiffer-Smadja N; Poissy J; Belhadi D; Diallo A; Lê MP; Peytavin G; Staub T; Greil R; Guedj J; Paiva JA; Costagliola D; Yazdanpanah Y; Burdet C; Mentré F;
Lancet Infect Dis; 2022 Feb; 22(2):209-221. PubMed ID: 34534511
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial.
Kalil AC; Mehta AK; Patterson TF; Erdmann N; Gomez CA; Jain MK; Wolfe CR; Ruiz-Palacios GM; Kline S; Regalado Pineda J; Luetkemeyer AF; Harkins MS; Jackson PEH; Iovine NM; Tapson VF; Oh MD; Whitaker JA; Mularski RA; Paules CI; Ince D; Takasaki J; Sweeney DA; Sandkovsky U; Wyles DL; Hohmann E; Grimes KA; Grossberg R; Laguio-Vila M; Lambert AA; Lopez de Castilla D; Kim E; Larson L; Wan CR; Traenkner JJ; Ponce PO; Patterson JE; Goepfert PA; Sofarelli TA; Mocherla S; Ko ER; Ponce de Leon A; Doernberg SB; Atmar RL; Maves RC; Dangond F; Ferreira J; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd L; Tomashek KM; Beigel JH;
Lancet Respir Med; 2021 Dec; 9(12):1365-1376. PubMed ID: 34672949
[TBL] [Abstract][Full Text] [Related]
6. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
; Pan H; Peto R; Henao-Restrepo AM; Preziosi MP; Sathiyamoorthy V; Abdool Karim Q; Alejandria MM; Hernández García C; Kieny MP; Malekzadeh R; Murthy S; Reddy KS; Roses Periago M; Abi Hanna P; Ader F; Al-Bader AM; Alhasawi A; Allum E; Alotaibi A; Alvarez-Moreno CA; Appadoo S; Asiri A; Aukrust P; Barratt-Due A; Bellani S; Branca M; Cappel-Porter HBC; Cerrato N; Chow TS; Como N; Eustace J; García PJ; Godbole S; Gotuzzo E; Griskevicius L; Hamra R; Hassan M; Hassany M; Hutton D; Irmansyah I; Jancoriene L; Kirwan J; Kumar S; Lennon P; Lopardo G; Lydon P; Magrini N; Maguire T; Manevska S; Manuel O; McGinty S; Medina MT; Mesa Rubio ML; Miranda-Montoya MC; Nel J; Nunes EP; Perola M; Portolés A; Rasmin MR; Raza A; Rees H; Reges PPS; Rogers CA; Salami K; Salvadori MI; Sinani N; Sterne JAC; Stevanovikj M; Tacconelli E; Tikkinen KAO; Trelle S; Zaid H; Røttingen JA; Swaminathan S
N Engl J Med; 2021 Feb; 384(6):497-511. PubMed ID: 33264556
[TBL] [Abstract][Full Text] [Related]
7. Remdesivir for the Treatment of Covid-19 - Final Report.
Beigel JH; Tomashek KM; Dodd LE; Mehta AK; Zingman BS; Kalil AC; Hohmann E; Chu HY; Luetkemeyer A; Kline S; Lopez de Castilla D; Finberg RW; Dierberg K; Tapson V; Hsieh L; Patterson TF; Paredes R; Sweeney DA; Short WR; Touloumi G; Lye DC; Ohmagari N; Oh MD; Ruiz-Palacios GM; Benfield T; Fätkenheuer G; Kortepeter MG; Atmar RL; Creech CB; Lundgren J; Babiker AG; Pett S; Neaton JD; Burgess TH; Bonnett T; Green M; Makowski M; Osinusi A; Nayak S; Lane HC;
N Engl J Med; 2020 Nov; 383(19):1813-1826. PubMed ID: 32445440
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhou F; Zhang D; Zhao J; Du R; Hu Y; Cheng Z; Gao L; Jin Y; Luo G; Fu S; Lu Q; Du G; Wang K; Lu Y; Fan G; Zhang Y; Liu Y; Ruan S; Liu W; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Trials; 2020 May; 21(1):422. PubMed ID: 32448345
[TBL] [Abstract][Full Text] [Related]
9. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
WHO Solidarity Trial Consortium
Lancet; 2022 May; 399(10339):1941-1953. PubMed ID: 35512728
[TBL] [Abstract][Full Text] [Related]
10. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Goldman JD; Lye DCB; Hui DS; Marks KM; Bruno R; Montejano R; Spinner CD; Galli M; Ahn MY; Nahass RG; Chen YS; SenGupta D; Hyland RH; Osinusi AO; Cao H; Blair C; Wei X; Gaggar A; Brainard DM; Towner WJ; Muñoz J; Mullane KM; Marty FM; Tashima KT; Diaz G; Subramanian A;
N Engl J Med; 2020 Nov; 383(19):1827-1837. PubMed ID: 32459919
[TBL] [Abstract][Full Text] [Related]
11. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial.
Wang Y; Zhang D; Du G; Du R; Zhao J; Jin Y; Fu S; Gao L; Cheng Z; Lu Q; Hu Y; Luo G; Wang K; Lu Y; Li H; Wang S; Ruan S; Yang C; Mei C; Wang Y; Ding D; Wu F; Tang X; Ye X; Ye Y; Liu B; Yang J; Yin W; Wang A; Fan G; Zhou F; Liu Z; Gu X; Xu J; Shang L; Zhang Y; Cao L; Guo T; Wan Y; Qin H; Jiang Y; Jaki T; Hayden FG; Horby PW; Cao B; Wang C
Lancet; 2020 May; 395(10236):1569-1578. PubMed ID: 32423584
[TBL] [Abstract][Full Text] [Related]
12. Association of Remdesivir Treatment With Survival and Length of Hospital Stay Among US Veterans Hospitalized With COVID-19.
Ohl ME; Miller DR; Lund BC; Kobayashi T; Richardson Miell K; Beck BF; Alexander B; Crothers K; Vaughan Sarrazin MS
JAMA Netw Open; 2021 Jul; 4(7):e2114741. PubMed ID: 34264329
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis.
Piscoya A; Ng-Sueng LF; Parra Del Riego A; Cerna-Viacava R; Pasupuleti V; Roman YM; Thota P; White CM; Hernandez AV
PLoS One; 2020; 15(12):e0243705. PubMed ID: 33301514
[TBL] [Abstract][Full Text] [Related]
14. Compassionate Use of Remdesivir for Patients with Severe Covid-19.
Grein J; Ohmagari N; Shin D; Diaz G; Asperges E; Castagna A; Feldt T; Green G; Green ML; Lescure FX; Nicastri E; Oda R; Yo K; Quiros-Roldan E; Studemeister A; Redinski J; Ahmed S; Bernett J; Chelliah D; Chen D; Chihara S; Cohen SH; Cunningham J; D'Arminio Monforte A; Ismail S; Kato H; Lapadula G; L'Her E; Maeno T; Majumder S; Massari M; Mora-Rillo M; Mutoh Y; Nguyen D; Verweij E; Zoufaly A; Osinusi AO; DeZure A; Zhao Y; Zhong L; Chokkalingam A; Elboudwarej E; Telep L; Timbs L; Henne I; Sellers S; Cao H; Tan SK; Winterbourne L; Desai P; Mera R; Gaggar A; Myers RP; Brainard DM; Childs R; Flanigan T
N Engl J Med; 2020 Jun; 382(24):2327-2336. PubMed ID: 32275812
[TBL] [Abstract][Full Text] [Related]
15. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
16. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
Kalil AC; Patterson TF; Mehta AK; Tomashek KM; Wolfe CR; Ghazaryan V; Marconi VC; Ruiz-Palacios GM; Hsieh L; Kline S; Tapson V; Iovine NM; Jain MK; Sweeney DA; El Sahly HM; Branche AR; Regalado Pineda J; Lye DC; Sandkovsky U; Luetkemeyer AF; Cohen SH; Finberg RW; Jackson PEH; Taiwo B; Paules CI; Arguinchona H; Erdmann N; Ahuja N; Frank M; Oh MD; Kim ES; Tan SY; Mularski RA; Nielsen H; Ponce PO; Taylor BS; Larson L; Rouphael NG; Saklawi Y; Cantos VD; Ko ER; Engemann JJ; Amin AN; Watanabe M; Billings J; Elie MC; Davey RT; Burgess TH; Ferreira J; Green M; Makowski M; Cardoso A; de Bono S; Bonnett T; Proschan M; Deye GA; Dempsey W; Nayak SU; Dodd LE; Beigel JH;
N Engl J Med; 2021 Mar; 384(9):795-807. PubMed ID: 33306283
[TBL] [Abstract][Full Text] [Related]
17. Remdesivir for Adults With COVID-19 : A Living Systematic Review for American College of Physicians Practice Points.
Wilt TJ; Kaka AS; MacDonald R; Greer N; Obley A; Duan-Porter W
Ann Intern Med; 2021 Feb; 174(2):209-220. PubMed ID: 33017170
[TBL] [Abstract][Full Text] [Related]
18. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
20. Remdesivir for the treatment of COVID-19: a living systematic review.
Verdugo-Paiva F; Acuña MP; Solá I; Rada G;
Medwave; 2020 Dec; 20(11):e8080. PubMed ID: 33361753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
